Librela: Clinical Experience & Recommendations for Its Use in Canine Osteoarthritis

Librela™ (bedinvetmab injection) is a recently approved monoclonal antibody that targets nerve growth factor (NGF) in dogs with chronic osteoarthritis (OA) pain. This presentation will focus on how the monoclonal antibody works and share clinical case recommendations for its use in the management of pain associated with chronic OA. The science behind Librela and monoclonal antibodies, how they affect chronic pain perception, their potential adverse effects, and results seen in various cases will also be reviewed.

Not looking for CE credit for this course? You can skip entering your information below and proceed to viewing the webinar here.